Between a new law aimed at springboarding treatments and a new administration promising to steamroll regulations, the federal government seems primed to approve more prescription drugs — and to do so faster. But one unintended consequence could be a waste of taxpayer dollars.

Whether the Food and Drug Administration should hasten drug approvals is a matter of vigorous debate from a scientific and safety standpoint. But many critics of that approach also make another argument that has been largely overlooked: More drug approvals could mean more unnecessary public spending.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • False premise. Read the recent WSJ piece showing that NONE of the top 20 selling drugs have been approved in the last decade.

  • making billions at the expenses of dumb Americans. That’s awesome. America is really great again!

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy